Paula Abola is a clinical researcher and academic with a strong focus on Parkinson’s disease, clinical drug development, and chemical biology. She has earned advanced degrees in Clinical Research, Clinical Drug Development, and Medicinal Chemistry & Chemical Biology, completing dissertations that explored knowledge disparities and shared decision-making in Parkinson’s disease, as well as comparative efficacy studies of pharmacological interventions and novel synthetic approaches in chemical biology. Paula has extensive experience in higher education, serving as an adjunct professor at multiple international universities, where she designs and delivers graduate- and doctorate-level courses in systematic reviews, meta-analyses, survey research, research proposal writing, study design, statistical methods, and chemical biology, while also mentoring and supervising student research projects. Her work emphasizes bridging methodological rigor with practical applications in clinical and social research, including applications in pharmacological management and vaccine development. Paula’s research contributions are documented in 2 scholarly works, which have collectively received 2 citations, giving her an h-index of 1 and an i10-index of 0. Her academic and research endeavors reflect a dedication to advancing knowledge in clinical pharmacology, research methodology, and chemical biology while fostering the development of future researchers through mentorship and teaching.
Featured Publications
Abola, P., Lefebvre, K., & Wolden, M. (2025). Influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for Parkinson’s disease. American Journal of Medical and Clinical Research & Reviews, 4(1), 1–16.
Abola, P., Wolden, M. (2024). Monoamine oxidase-B inhibitor rasagiline effects on motor and non-motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 13(3), 27–56.
Abola, P., & Jabishvili, G. (2025). Incidence of adverse and safety events in individuals with Parkinson’s disease treated with catechol-O-methyltransferase inhibitor opicapone as an add-on to levodopa treatment. Prospects in Pharmaceutical Sciences.
Abola, P., & Lefebvre, K. (2025). Technological advancements in the reduction of Parkinsonian tremor: A scoping review. Topics in Geriatric Rehabilitation, 41(3), 162–170.
Abola, P., Wolden, B., & Wolden, M. (2025). Journal of Neurology & Neuropsychiatry. Neuropsychiatry, 2(1).
Abola, P., & Lefebvre, K. (2025). Technological advancements in the detection and quantification of Parkinsonian tremor: A scoping review. Topics in Geriatric Rehabilitation, 41(3), 154–161.
Abola, P., & Wolden, M. (2025). Intra-individual variations in voice variables among individuals with and without Parkinson’s disease. Cureus, 17(3).
Abola, P., & Lefebvre, K. M. (2025). Technological advancements in the rehabilitation of Parkinsonian tremor: A systematic review. 2025 Combined Sections Meeting (CSM).